{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:15:15Z","timestamp":1793837715620,"version":"4.6.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9lius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003127","name":"Punainen Risti Veripalvelu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003127","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.xcrm.2025.102016","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:55:15Z","timestamp":1742295315000},"page":"102016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7217-2974","authenticated-orcid":false,"given":"Tine J.","family":"Monberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santeri A.","family":"Pakola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Albieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Ellebaek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Donia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke L.","family":"Eefsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troels H.","family":"Borch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana V.","family":"Kudling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torben","family":"Lorentzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helle W.","family":"Hendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathrine","family":"Lorentzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke B.","family":"Holmstroem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Khammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Kistler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o M.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.A.","family":"Clubb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyna","family":"Haybout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C.W.","family":"Westergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zcan","family":"Met","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafne C.A.","family":"Quixabeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Jirovec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riikka","family":"Havunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvi","family":"Sorsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Cervera-Carrascon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Dreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102016_bib1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/oncolo\/oyae136","article-title":"Lifileucel: FDA-approved T-cell therapy for melanoma","volume":"29","author":"Kwong","year":"2024","journal-title":"The Oncologist"},{"key":"10.1016\/j.xcrm.2025.102016_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215452","article-title":"Oncolytic viruses: Newest frontier for cancer immunotherapy","volume":"13","author":"Rahman","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2025.102016_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02460","article-title":"CAR-T cells and oncolytic viruses: Joining forces to overcome the solid tumor challenge","volume":"9","author":"Guedan","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102016_bib4","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined with Pembrolizumab for Advanced Melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102016_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.21037\/atm-2023-5","article-title":"Combination strategies incorporating oncolytic viruses and immune checkpoint inhibitors for advanced melanoma: what is the evidence?","volume":"11","author":"Wongariyapak","year":"2023","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.xcrm.2025.102016_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103705","article-title":"Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis","volume":"175","author":"Stahlie","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.xcrm.2025.102016_bib7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.semcancer.2021.05.019","article-title":"Optimal timing of PD-1 blockade in combination with oncolytic virus therapy","volume":"86","author":"Nguyen","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.xcrm.2025.102016_bib8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.omto.2020.03.003","article-title":"Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors","volume":"17","author":"Cervera-Carrascon","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.xcrm.2025.102016_bib9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","article-title":"Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy","volume":"4","author":"Havunen","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.xcrm.2025.102016_bib10","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/mt.2016.137","article-title":"Adenoviral Delivery of Tumor Necrosis Factor-\u03b1 and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma","volume":"24","author":"Siurala","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2025.102016_bib11","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1136046","article-title":"Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting","volume":"5","author":"Siurala","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.xcrm.2025.102016_bib12","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.ymthe.2018.06.001","article-title":"Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy","volume":"26","author":"Santos","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2025.102016_bib13","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1002\/ijc.30839","article-title":"Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy","volume":"141","author":"Santos","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102016_bib14","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1158\/1078-0432.CCR-23-3874","article-title":"Safety, efficacy, and biological data of T\u00a0cell-enabling oncolytic adenovirus TILT-123 in advanced solid cancers from the TUNIMO monotherapy phase I trial","volume":"30","author":"Pakola","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102016_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.iotech.2024.100726","article-title":"Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma","volume":"24","author":"Monberg","year":"2024","journal-title":"Immuno-Oncology and Technology"},{"key":"10.1016\/j.xcrm.2025.102016_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12041027","article-title":"Primary resistance to pd-1-based immunotherapy\u2014 a study in 319 patients with stage iv melanoma","volume":"12","author":"Amaral","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2025.102016_bib17","doi-asserted-by":"crossref","first-page":"e000341","DOI":"10.1136\/jitc-2019-000341","article-title":"Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma","volume":"8","author":"Klemen","year":"2020","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102016_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.omto.2018.10.005","article-title":"Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus","volume":"11","author":"Havunen","year":"2018","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.xcrm.2025.102016_bib19","doi-asserted-by":"crossref","unstructured":"Wong M.K., Sacco, J.J., Robert, C., Michels, J., Bowles, T.L., In, G.K., Tsai, K.K., Lebbe, C., Gaudy-Marqueste, C., Mu\u00f1oz Couselo, E., et\u00a0al., Efficacy and safety of RP1 combined with nivolumab in patients with anti\u2013PD-1\u2013failed melanoma from the IGNYTE clinical trial. (2024).","DOI":"10.1200\/JCO.2024.42.16_suppl.9517"},{"key":"10.1016\/j.xcrm.2025.102016_bib20","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102016_bib21","doi-asserted-by":"crossref","first-page":"e008640","DOI":"10.1136\/jitc-2023-008640","article-title":"Biomarkers for response to TIL therapy : a comprehensive review","volume":"12","author":"Fern\u00e1ndez","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.xcrm.2025.102016_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: Pooled analysis of consecutive cohorts","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.xcrm.2025.102016_bib23","first-page":"2023","article-title":"LONG-TERM EFFICACY AND SAFETY OF LIFILEUCEL TUMOR-INFILTRATING LYMPHOCYTE (TIL) CELL THERAPY IN PATIENTS WITH ADVANCED MELANOMA: A 4-YEAR ANALYSIS OF THE C-144\u201301 STUDY","volume":"11","author":"Medina","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.xcrm.2025.102016_bib24","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1089\/hum.2013.123","article-title":"[18F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer","volume":"24","author":"Koski","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.xcrm.2025.102016_bib25","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1148\/rg.2021200093","article-title":"Reassessing patterns of response to immunotherapy with pet: From morphology to metabolism","volume":"41","author":"Costa","year":"2021","journal-title":"Radiographics"},{"key":"10.1016\/j.xcrm.2025.102016_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2023.01.002","article-title":"Preexisting immunity: Barrier or bridge to effective oncolytic virus therapy?","volume":"70","author":"Groeneveldt","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.xcrm.2025.102016_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-023-06623-2","article-title":"Clinical trial links oncolytic immunoactivation to survival in glioblastoma","volume":"623","author":"Ling","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2025.102016_bib28","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T\u00a0cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.xcrm.2025.102016_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104539","article-title":"A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases","volume":"90","author":"Raeber","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.xcrm.2025.102016_bib30","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102016_bib31","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.1745-7254.2008.00889.x","article-title":"Tumor necrosis factor and cancer, buddies or foes?","volume":"29","author":"Wang","year":"2008","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.xcrm.2025.102016_bib32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood-2005-11-4567","article-title":"TNF downmodulates the function of human CD4+ CD25hi T-regulatory cells","volume":"108","author":"Valencia","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.xcrm.2025.102016_bib33","first-page":"1","article-title":"The TNF Paradox in Cancer Progression and Immunotherapy","volume":"10","author":"Montfort","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2025.102016_bib34","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3349\/ymj.2019.60.2.126","article-title":"Tumor Necrosis Factor and Regulatory T Cells","volume":"60","author":"Jung","year":"2019","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.xcrm.2025.102016_bib35","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jcyt.2014.02.004","article-title":"Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor","volume":"16","author":"Donia","year":"2014","journal-title":"Cytotherapy"},{"key":"10.1016\/j.xcrm.2025.102016_bib36","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00002371-199112000-00003","article-title":"High-fold expansion of human cytotoxic T-lymphocytes specific for autologous melanoma cells for use in immunotherapy","volume":"10","author":"Jotereau","year":"1991","journal-title":"J.\u00a0Immunother."},{"key":"10.1016\/j.xcrm.2025.102016_bib37","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/PL00006683","article-title":"High-scale expansion of melanoma-reactive TIL by a polyclonal stimulus: Predictability and relation with disease advancement","volume":"50","author":"Pandolfino","year":"2001","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.xcrm.2025.102016_bib38","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1158\/1078-0432.CCR-22-3853","article-title":"Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma","volume":"29","author":"Draghi","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102016_bib39","series-title":"Data analysis","author":"Wickham","year":"2016"},{"key":"10.1016\/j.xcrm.2025.102016_bib40","article-title":"SmulTCan: A Shiny application for multivariable survival analysis of TCGA data with gene sets","volume":"137","author":"Alboukadel Kassambara","year":"2021","journal-title":"Computers in Biology and Medicine"},{"key":"10.1016\/j.xcrm.2025.102016_bib41","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J.\u00a0Open Source Softw."},{"key":"10.1016\/j.xcrm.2025.102016_bib42","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125000898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379125000898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T21:39:43Z","timestamp":1762637983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379125000898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2666379125000898"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102016","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102016"}}